TrialInvestigational new drugs2016

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Paul L Swiecicki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.